Every material Form 8-K abrdn Life Sciences Investors has filed with the SEC since March 23, 2012, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Deloitte & Touche resigned as the independent auditor of Tekla Life Sciences Investors on September 6, 2023, citing an anticipated independence issue tied to a pending transaction between Tekla Capital Management LLC and abrdn Inc. The fund's board approved KPMG LLP as its auditor on September 7, 2023, for the fiscal year ending September 30, 2023, and the filing reports no disagreements or reportable events with Deloitte.
Deloitte resigned on September 6, 2023, due to an anticipated independence issue linked to a pending Tekla Capital Management LLC and abrdn Inc. transaction.
The Audit Committee approved the resignation on September 7, 2023, and the board approved KPMG LLP the same day.
Deloitte's reports for the fiscal years ended September 30, 2022 and 2021 contained no adverse or disclaimer opinion and were not qualified or modified.
No disagreements or reportable events with Deloitte occurred in the two most recent fiscal years or the interim period through September 6, 2023.
The Board of Trustees of H&Q Life Sciences Investors authorized a renewal of the Fund's share repurchase program, as announced in a March 22, 2013 press release. The renewed program lets the Fund buy back up to 12% of its outstanding common shares in the open market through July 10, 2014, a one-year extension of the current program's July 10, 2013 end date. The Board says the program aims to narrow the discount between the share price and net asset value per share.
Renewed program allows open-market purchases of up to 12% of outstanding common shares.
Renewed program runs for one year, ending July 10, 2014; the current program ends July 10, 2013.
Tekla Capital Management LLC, the Fund's investment adviser, will decide the amount and timing of repurchases.
The filing states there is no assurance of purchases at any specific discount level, amount or date.
H&Q Life Sciences Investors said its Board of Trustees authorized a renewal of the Fund's share repurchase program. The renewed program would let the Fund buy up to 12% of its outstanding common shares in the open market for one year, starting July 11, 2012, after the current program ends on July 10, 2012. The Board said the aim is to increase net asset value per share and possibly narrow the discount between market price and net asset value.
Renewed program allows open-market purchases of up to 12% of outstanding common shares
Current program runs through July 10, 2012; renewal covers the one-year period beginning July 11, 2012
Repurchase amount and timing are at the discretion of Hambrecht & Quist Capital Management LLC, the Fund's adviser
The filing states there is no assurance shares will be bought at any specific discount or amount, or that market price will rise
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every abrdn Life Sciences Investors filing is on SEC EDGAR ↗. 8-K briefs of other companies →